Early Stage Biotech IPOs Join Late-stage Plays In Appealing to Investors
This article was originally published in The Pink Sheet Daily
With Epizyme as a top performing biotech IPO and bluebird bio primed to go out soon, investor appetite would seem whetted for early stage biotechs on the public market. With improving overall IPO performance, these returns could again become meaningful for more than a few life science VCs.
You may also be interested in...
The personalized immunotherapy developer partnered with Korea’s Green Cross and Russia’s Pharmstandard but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.
A new fund offering access to European translational research focused on rare diseases has high-profile backers and reunites key players in the successful Prosensa IPO.
Life science VCs are posting strong across-the-board returns, allowing some firms to raise new funds larger than their prior vehicles. Still, the contraction that began nearly five years ago is still thwarting other firms’ efforts to press on through hard times.